CPHI
China Pharma Holdings, Inc.1.4400
-0.0900-5.88%
Dec 16, 3:59:56 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
7.23MP/E (TTM)
-Basic EPS (TTM)
-1.02Dividend Yield
0%Recent Filings
8-K
Acquires patent for $6.93M stock
China Pharma's Helpson subsidiary signed a Technology Transfer Agreement on February 26, 2026, acquiring Xiaoyan Zhang's patent for Prinsepia Utilis Esterol Sublingual Tablets and preparation method, valid until 2038. Payment: $6.93 million in 12,600,000 restricted common shares at $0.55 each. Transferor provides technical services. Deal expands IP toolkit.
8-K
Acquires Topiroxostat patent for shares
China Pharma's Helpson subsidiary signed a Technology Transfer Agreement on February 5, 2026, acquiring the Topiroxostat Nanoemulsion patent (No. 201610170435X, valid to 2036) from Xiaoyun Chen for $8.82 million in 12,600,000 restricted shares at $0.70 each, closing by February 20. Chen provides technical services including R&D and registration support; post-launch, she gets 3% of net profits. Deal bolsters pharma pipeline. Equity issued under Regulation S exemption.
8-K
Annual meeting approves directors, split
China Pharma Holdings held its annual meeting on December 30, 2025, with 69.71% quorum. Stockholders elected independent directors Gene Michael Bennett, Yingwen Zhang, and Baowen Dong. They approved a discretionary reverse stock split up to 1:20 and Amendment No.3 to the 2010 Long-Term Incentive Plan. Board decides split timing.
8-K
Acquires Ipragliflozin patent for stock
China Pharma's Helpson subsidiary acquired an Ipragliflozin tablets patent from Juan Zhang for $9.8 million in 7 million restricted shares at $1.40 each, effective December 22, 2025. Transferor to provide R&D and registration support. Patent bolsters diabetes drug pipeline. Shares issued under Regulation S exemption.
8-K
Acquires Captopril patent for shares
China Pharma's Helpson subsidiary signed a Technology Transfer Agreement on December 4, 2025, acquiring a Captopril microcapsule patent for $6.3 million in 3,500,000 restricted common shares at $1.80 each. The transferor will provide technical services like R&D and registration support. Stock issued unregistered under Regulation S. Patent bolsters drug tech pipeline.
IPO
Employees
Sector
Industry
AMPH
Amphastar Pharmaceuticals, Inc.
25.61-0.70
BGM
BGM Group Ltd.
5.01-0.16
COSM
Cosmos Health Inc.
0.50+0.09
CWBHF
Charlotte's Web Holdings Inc.
0.15+0.00
RGC
Regencell Bioscience Holdings L
16.70-0.56
SBFM
Sunshine Biopharma Inc.
1.38-0.01
SXTC
China SXT Pharmaceuticals, Inc.
1.64+0.19
TEVA
Teva Pharmaceutical Industries
30.10-0.03
UPC
Universe Pharmaceuticals Inc
3.68+0.05
VTRS
Viatris Inc.
11.46-0.20